Literature DB >> 17970220

The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control.

Robert C Goldman1, Kevin V Plumley, Barbara E Laughon.   

Abstract

Tuberculosis (TB) is a devastating disease caused by Mycobacterium tuberculosis that killed an estimated 4000-5000 person each day during 2005. Although infections with drug sensitive strains can be effectively cured with a 6 to 9 month regimen of multiple antibiotics, the inability to deliver and complete appropriate courses of therapy on a global level has led to the selection of resistant strains over the past 50 years. The selection and spread of multiple drug resistant M. tuberculosis continued for decades leading to two operationally distinct forms of the disease, multiple drug resistant (MDR-TB) and extensively drug resistant (XDR-TB). The estimate for MDR-TB and XDR-TB cases for 2005 were 424,000 and 27,000 respectively, and the situation is worst in areas with high incidences of HIV infection. The outcome was predictable based on basic microbiological principles, and the resultant and future epidemic effectively modeled mathematically. This situation was brought to the forefront when an outbreak of XDR-TB occurred in Tugela Ferry, KwaZulu-Natal, South Africa, in 2005 and began to spread. Unfortunately, we do not know the true extent of XDR-TB globally. However, all signs point to an emerging epidemic of TB infections that will be difficult, if not impossible to cure. A few new drugs are in clinical trials, but it is too early to know the final outcome; some may fail, and none will be available for several years. The situation will continue to worsen unless more resources are made available to discover and deliver better treatment options.

Entities:  

Mesh:

Year:  2007        PMID: 17970220     DOI: 10.2174/187152607781001844

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  28 in total

1.  Isoniazid metal complex reactivity and insights for a novel anti-tuberculosis drug design.

Authors:  Eduardo Henrique Silva Sousa; Luiz Augusto Basso; Diógenes S Santos; Izaura Cirino Nogueira Diógenes; Elisane Longhinotti; Luiz Gonzaga de França Lopes; Icaro de Sousa Moreira
Journal:  J Biol Inorg Chem       Date:  2011-09-28       Impact factor: 3.358

2.  Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.

Authors:  Jean C Sung; Lucila Garcia-Contreras; Jarod L Verberkmoes; Charles A Peloquin; Katharina J Elbert; Anthony J Hickey; David A Edwards
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

3.  Acyldepsipeptide antibiotics kill mycobacteria by preventing the physiological functions of the ClpP1P2 protease.

Authors:  Kirsten Famulla; Peter Sass; Imran Malik; Tatos Akopian; Olga Kandror; Marina Alber; Berthold Hinzen; Helga Ruebsamen-Schaeff; Rainer Kalscheuer; Alfred L Goldberg; Heike Brötz-Oesterhelt
Journal:  Mol Microbiol       Date:  2016-04-01       Impact factor: 3.501

Review 4.  The Mycobacterium tuberculosis MEP (2C-methyl-d-erythritol 4-phosphate) pathway as a new drug target.

Authors:  Hyungjin Eoh; Patrick J Brennan; Dean C Crick
Journal:  Tuberculosis (Edinb)       Date:  2008-09-14       Impact factor: 3.131

5.  6-Oxo and 6-thio purine analogs as antimycobacterial agents.

Authors:  Ashish K Pathak; Vibha Pathak; Lainne E Seitz; William J Suling; Robert C Reynolds
Journal:  Bioorg Med Chem       Date:  2013-02-04       Impact factor: 3.641

6.  Crystal structure of the transcriptional regulator Rv1219c of Mycobacterium tuberculosis.

Authors:  Nitin Kumar; Abhijith Radhakrishnan; Catherine C Wright; Tsung-Han Chou; Hsiang-Ting Lei; Jani Reddy Bolla; Marios L Tringides; Kanagalaghatta R Rajashankar; Chih-Chia Su; Georgiana E Purdy; Edward W Yu
Journal:  Protein Sci       Date:  2014-03-10       Impact factor: 6.725

7.  Crystal structure of the transcriptional regulator Rv0678 of Mycobacterium tuberculosis.

Authors:  Abhijith Radhakrishnan; Nitin Kumar; Catherine C Wright; Tsung-Han Chou; Marios L Tringides; Jani Reddy Bolla; Hsiang-Ting Lei; Kanagalaghatta R Rajashankar; Chih-Chia Su; Georgiana E Purdy; Edward W Yu
Journal:  J Biol Chem       Date:  2014-04-15       Impact factor: 5.157

Review 8.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

9.  Synthesis of deoxygenated alpha(1-->5)-linked arabinofuranose disaccharides as substrates and inhibitors of arabinosyltransferases of Mycobacterium tuberculosis.

Authors:  Ashish K Pathak; Vibha Pathak; William J Suling; James R Riordan; Sudagar S Gurcha; Gurdyal S Besra; Robert C Reynolds
Journal:  Bioorg Med Chem       Date:  2008-11-18       Impact factor: 3.641

10.  GenHtr: a tool for comparative assessment of genetic heterogeneity in microbial genomes generated by massive short-read sequencing.

Authors:  Gongxin Yu
Journal:  BMC Bioinformatics       Date:  2010-10-12       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.